DK1225878T3 - RAR-gamma-selektive retinoidagonister til behandling af emfysem - Google Patents

RAR-gamma-selektive retinoidagonister til behandling af emfysem

Info

Publication number
DK1225878T3
DK1225878T3 DK00972754T DK00972754T DK1225878T3 DK 1225878 T3 DK1225878 T3 DK 1225878T3 DK 00972754 T DK00972754 T DK 00972754T DK 00972754 T DK00972754 T DK 00972754T DK 1225878 T3 DK1225878 T3 DK 1225878T3
Authority
DK
Denmark
Prior art keywords
rar
emphysema
treatment
retinoid agonists
selective retinoid
Prior art date
Application number
DK00972754T
Other languages
Danish (da)
English (en)
Inventor
Paula Nanette Belloni
Michael Klaus
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK1225878T3 publication Critical patent/DK1225878T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK00972754T 1999-10-19 2000-10-13 RAR-gamma-selektive retinoidagonister til behandling af emfysem DK1225878T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16041599P 1999-10-19 1999-10-19
PCT/EP2000/010076 WO2001030326A1 (en) 1999-10-19 2000-10-13 Treatment of emphysema using rar selective retinoid agonists

Publications (1)

Publication Number Publication Date
DK1225878T3 true DK1225878T3 (da) 2007-03-05

Family

ID=22576814

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00972754T DK1225878T3 (da) 1999-10-19 2000-10-13 RAR-gamma-selektive retinoidagonister til behandling af emfysem

Country Status (34)

Country Link
US (1) US6300350B1 (pt)
EP (1) EP1225878B1 (pt)
JP (2) JP4074458B2 (pt)
KR (1) KR100485581B1 (pt)
CN (1) CN1201730C (pt)
AR (1) AR029648A1 (pt)
AT (1) ATE344661T1 (pt)
AU (1) AU777325B2 (pt)
BR (1) BR0015225A (pt)
CA (1) CA2387844C (pt)
CY (1) CY1105941T1 (pt)
CZ (1) CZ20021657A3 (pt)
DE (1) DE60031790T2 (pt)
DK (1) DK1225878T3 (pt)
ES (1) ES2274810T3 (pt)
HK (1) HK1051002A1 (pt)
HR (1) HRP20020329A2 (pt)
HU (1) HUP0203295A3 (pt)
IL (1) IL149151A0 (pt)
JO (1) JO2178B1 (pt)
MA (1) MA26835A1 (pt)
MX (1) MXPA02003843A (pt)
MY (1) MY129001A (pt)
NO (1) NO328738B1 (pt)
NZ (1) NZ518118A (pt)
PE (1) PE20010678A1 (pt)
PL (1) PL357499A1 (pt)
PT (1) PT1225878E (pt)
RS (1) RS50165B (pt)
RU (1) RU2257383C2 (pt)
TR (1) TR200201071T2 (pt)
TW (1) TWI288639B (pt)
WO (1) WO2001030326A1 (pt)
ZA (1) ZA200202576B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061233A2 (en) * 1999-04-14 2000-10-19 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease involving a specific rar-gamma agonist
WO2003024920A1 (en) 2001-09-18 2003-03-27 F. Hoffmann-La Roche Ag Substituted urea retinoid agonists ii
WO2003024921A1 (en) * 2001-09-18 2003-03-27 F. Hoffmann-La Roche Ag Alkyl urea retinoid agonists i
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
GB2388581A (en) 2003-08-22 2003-11-19 Danisco Coated aqueous beads
JP4926707B2 (ja) 2003-08-22 2012-05-09 ダニスコ エイ/エス 封入化抗菌材料
WO2008057933A2 (en) * 2006-11-02 2008-05-15 Aestus Therapeutics, Inc. Methods of treating neuropathic pain by modulation of glycogenolysis or glycolysis pathways
HUE059024T2 (hu) 2010-09-01 2022-10-28 Univ Jefferson Összetétel és módszer az izom helyreállítására és regenerációjára
KR102055395B1 (ko) 2011-06-24 2019-12-12 쥐알아이 바이오,아이엔씨. 염증 질환의 예방 및 치료
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
US20140155381A1 (en) * 2011-07-29 2014-06-05 Erkan Baloglu Compounds and methods
KR20150095870A (ko) 2012-12-17 2015-08-21 패리온 사이언스 인코퍼레이티드 3,5-디아미노-6-클로로-n-(n-(4-페닐부틸)카르밤이미도일)피라진-2-카르복스아미드 화합물
EP3150585A1 (en) 2012-12-17 2017-04-05 Parion Sciences, Inc. Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity
EP4083029A1 (en) 2013-08-20 2022-11-02 University of Washington through its Center for Commercialization Novel and specific inhibitors of cytochrome p450 26 retinoic acid hydroxylase
US10500232B2 (en) 2013-08-26 2019-12-10 The J. David Gladstone Ins., a testamentary trust established under the Will of J. David Gladstone Small molecule cellular reprogramming to generate neuronal cells
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0139216B1 (ko) 1988-04-11 1998-05-01 제임스 엠. 캐내지 레티노이드 유사활성을 갖는 페놀 또는 벤조산의 테트랄린 에스테르
CA2129773C (en) * 1993-09-02 2007-05-01 Michael Klaus Aromatic carboxylic acid derivatives
US5498795A (en) * 1994-12-29 1996-03-12 Allergan, Inc. Acetylenes disubstituted with hydroxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
US5807900A (en) * 1995-03-31 1998-09-15 Hoffmann-La Roche, Inc. Method for identifying compounds having increased activity for the repair of skin photodamage
US5624957A (en) * 1995-06-06 1997-04-29 Bristol-Myers Squibb Company Rary-specific retinobenzoic acid derivatives
FR2739557B1 (fr) * 1995-10-09 1997-11-14 Cird Galderma Utilisation d'un ligand agoniste specifique rar-gamma
US5726191A (en) * 1995-11-16 1998-03-10 Hoffmann-La Roche Inc. Aromatic carboxylic acid esters
FR2747041B1 (fr) 1996-04-05 1998-05-22 Cird Galderma Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des neuropathies
BR9814957A (pt) * 1997-11-12 2000-10-03 Hoffmann La Roche Tratamento de doenças imune mediadas por célula auxiliar "t" tipo 2 com antagonistas retinóides
US6083973A (en) * 1998-03-09 2000-07-04 Syntex (U.S.A.) Inc. Methods for inhibiting mucin secretion using RAR α selective antagonists
AU4222400A (en) 1999-04-14 2000-11-14 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease
WO2000061232A2 (en) * 1999-04-14 2000-10-19 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease involving a specific rar-beta antagonist
WO2000061233A2 (en) * 1999-04-14 2000-10-19 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease involving a specific rar-gamma agonist
EP1206436B1 (en) * 1999-08-02 2004-10-13 F. Hoffmann-La Roche Ag Retinoids for the treatment of emphysema
US6479670B1 (en) * 1999-08-25 2002-11-12 Hoffmann-La Roche Inc. Selective retinoid acid receptor agonists

Also Published As

Publication number Publication date
MXPA02003843A (es) 2002-09-30
NO20021823L (no) 2002-04-18
BR0015225A (pt) 2002-07-16
HUP0203295A2 (hu) 2003-01-28
DE60031790T2 (de) 2007-09-20
CY1105941T1 (el) 2011-04-06
JP2003512418A (ja) 2003-04-02
JP4850791B2 (ja) 2012-01-11
CZ20021657A3 (cs) 2002-10-16
CN1382042A (zh) 2002-11-27
PT1225878E (pt) 2007-01-31
AR029648A1 (es) 2003-07-10
YU29002A (sh) 2005-06-10
EP1225878B1 (en) 2006-11-08
KR100485581B1 (ko) 2005-04-27
JP4074458B2 (ja) 2008-04-09
ZA200202576B (en) 2003-09-23
PL357499A1 (en) 2004-07-26
ATE344661T1 (de) 2006-11-15
CA2387844C (en) 2009-04-14
ES2274810T3 (es) 2007-06-01
AU777325B2 (en) 2004-10-14
MY129001A (en) 2007-03-30
HRP20020329A2 (en) 2004-04-30
NO20021823D0 (no) 2002-04-18
NO328738B1 (no) 2010-05-03
WO2001030326A1 (en) 2001-05-03
KR20020043640A (ko) 2002-06-10
DE60031790D1 (de) 2006-12-21
RU2257383C2 (ru) 2005-07-27
AU1137401A (en) 2001-05-08
PE20010678A1 (es) 2001-07-04
TWI288639B (en) 2007-10-21
IL149151A0 (en) 2002-11-10
NZ518118A (en) 2004-02-27
HUP0203295A3 (en) 2003-04-28
JP2007302689A (ja) 2007-11-22
MA26835A1 (fr) 2004-12-20
RS50165B (sr) 2009-05-06
HK1051002A1 (en) 2003-07-18
JO2178B1 (en) 2003-04-23
TR200201071T2 (tr) 2002-08-21
CN1201730C (zh) 2005-05-18
CA2387844A1 (en) 2001-05-03
US6300350B1 (en) 2001-10-09
EP1225878A1 (en) 2002-07-31

Similar Documents

Publication Publication Date Title
DK2253620T3 (da) Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer
DK1772141T3 (da) Fremgangsmåde til gennemföring af krystallisation i fast tilstand
DK1147083T3 (da) Arylpiperazinyl-cyclohexylindolderivater til behandling af depression
DK1296935T3 (da) Fremgangsmåde til fremstilling af substituerede octanoylamider
DE60132651D1 (de) Positionsbestimmungssystem
DK1259512T3 (da) Pteridinforbindelser til behandling af psoreasis
DK2258688T3 (da) Pyridinon-derivater til behandling af aterosklerose
DK1225878T3 (da) RAR-gamma-selektive retinoidagonister til behandling af emfysem
DK1206436T3 (da) Retinoider til behandling af emfysem
DK1324970T3 (da) Retinoider til behandling af emfysem
DK1150991T3 (da) Præparater til behandling af inflammatoriske reaktioner
DK199800837A (da) Anlæg til behandling af emner
DE60202537D1 (de) Torpedostartsystem
DE60130137D1 (de) Kristallisationsverfahren
DE60134807D1 (de) Beschichtungssytem
DK1268482T3 (da) Pyranoindoler til behandling af glaukom
DE60214042D1 (de) Nass-trocken-reinigungssystem
DK0981950T3 (da) Fremgangsm,åde til formering af phyllocactus
DK1224181T3 (da) Substituerede pyrroler som antiproliferative midler til behandling af cancer
FI20012516A (fi) Päänviennin menetelmä
ITPR980020A1 (it) Incorniciatura rapida
ITMO20010226A0 (it) Apparato
DE50200113D1 (de) Spannbare Schelle
DE60201909D1 (de) Zoom-verfahren
DK1140984T3 (da) Selektive inhibitorer af MMP-12